SCHEDULE: FMR LLC Reports 13.2% Stake in Avalyn Pharma

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 13.2% of Avalyn Pharma Inc.'s common shares as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, indicating their beneficial ownership of Avalyn Pharma Inc. common shares.
• As of June 30, 2026, the aggregate amount beneficially owned is 5,835,259 shares, representing 13.2% of the class.
• FMR LLC holds sole voting power for 5,762,944 shares and sole dispositive power for 5,835,259 shares.
• Abigail P. Johnson has sole dispositive power for 5,835,259 shares.
• F-Prime Capital Partners Healthcare Fund V LP's interest in Avalyn Pharma Inc. common stock amounted to 2,284,535 shares, or 5.2% of the total outstanding shares at June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes rather than operational or financial performance.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson, potentially indicating confidence in the company's long-term prospects.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Negatives

• The filing does not provide any operational or financial performance data, limiting insight into the company's current health.
• The date of the event requiring the filing (June 30, 2026) is in the past, and the filing date is August 5, 2026, indicating a reporting lag.

Risks

• Potential for future changes in beneficial ownership by FMR LLC and Abigail P. Johnson, which could impact share price.
• Concentration of ownership among a few entities could influence corporate decisions.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future financial performance or strategic initiatives.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. The disclosure by FMR LLC and Abigail P. Johnson indicates a substantial investment in Avalyn Pharma, a biotechnology company, which is typical for large asset managers in this sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes, potentially influencing market perception.
• Management: Awareness of substantial institutional interest may impact strategic decision-making.

Next Steps

• Monitor future filings from FMR LLC and Abigail P. Johnson for any changes in beneficial ownership.
• Observe Avalyn Pharma Inc.'s operational and financial performance for insights into the company's strategic direction.

Key Dates

Keywords

Avalyn Pharma, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Shares, Institutional Investor, F-Prime Capital Partners